Testing a Trop2-targeting antibody-drug conjugate drug compared to the usual chemotherapy treatment for platinum-sensitive ovarian cancer that has progressed on prior maintenance PARP inhibitor therapy

NRG ONCOLOGY

Advancing Research. Improving Lives.™

ABOUT THE TRIAL

NRG-GY038 is a clinical trial for patients with ovarian cancer that is platinum-sensitive and has progressed on prior maintenance PARP inhibitor therapy.

We want to learn if we can delay your ovarian cancer growing or spreading by using a Trop-2 targeting antibody drug conjugate (sacituzumab govitecan-hziy) with bevacizumab.

ABOUT NRG ONCOLOGY

As one of the five research groups in the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on sex-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI. To contact NRG Oncology, call 267-519-6630 or email info@nrgoncology.org

Version date: 3/19/2026

Frequently Asked Questions

What is a clinical trial?
Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?
People who have ovarian cancer that is platinum-sensitive and has progressed on prior maintenance PARP inhibitor therapy.

Can I change my mind if I choose to take part in this study?
Yes. Taking part in this study is voluntary. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?
Everyone on the study will be randomly assigned to one of two treatment groups. Treatment group 1 will receive the usual chemotherapy to treat this type of cancer. Treatment group 2 will receive the study drug sacituzumab govitecan plus bevacizumab. Both treatment groups will receive maintenance bevacizumab.

How long will I be in this study?
You will continue to receive your assigned treatment for up to 10 months if you receive carboplatin, liposomal doxorubicin and bevacizumab or for up to seven and a half months if you receive sacituzumab govitecan-hziy. After either of these treatments you will receive maintenance bevacizumab until your disease worsens or you have unacceptable side effects. The study team will continue to follow your condition for up to five years after you finish treatment.

Are there side effects?
There may be. The most common side effects from the drugs used in this study are fever, infections, diarrhea, fatigue, high blood pressure, and excess protein in the urine. There may be some side effects of the drugs or combinations of drugs that your doctor does not yet know about. Your doctor will review all of the potential side effects with you.

MORE INFORMATION

Visit the National Cancer Institute website at https://www.cancer.gov for more information about studies or general information about cancer.
You may also call: 1-(800)-4-CANCER (1-800-422-6237).